Inge Zomerdijk is currently working at the pharmacovigilance department of the Medicines Evaluation Board (MEB) in the Netherlands since 2010. She is a senior pharmacovigilance assessor and as a regulator she has experiences in assessing Risk Management Plans, national implementation of risk minimization measures as well as benefit-risk assessments of both new drug applications or post marketing follow up. In 2015 she completed her PhD research at the Erasmus Medical Center in Rotterdam, the Netherlands. Her research was specifically focused on how to evaluate risk minimization measures, the impact of these measures on the benefit-risk balance of drugs and translating possibilities and challenges to practical implications for regulatory authorities and industry. She is still involved in research that the MEB in collaboration with universities is conducting in the field of outcome of risk minimisation measures.